Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study
Alexander Häge,Kenneth K C Man,Sarah K Inglis,Jan Buitelaar,Sara Carucci,Marina Danckaerts,Ralf W Dittmann,Bruno Falissard,Peter Garas,Chris Hollis,Kerstin Konrad,Hanna Kovshoff,Elizabeth Liddle,Suzanne McCarthy,Antje Neubert,Peter Nagy,Eric Rosenthal,Edmund J S Sonuga-Barke,Alessandro Zuddas,Ian C K Wong,David Coghill,Tobias Banaschewski,Kenneth K. C. Man,Sarah K. Inglis,Ralf W. Dittmann,Edmund J. S. Sonuga-Barke,Ian C. K. Wong
DOI: https://doi.org/10.1177/10870547241232337
2024-02-23
Journal of Attention Disorders
Abstract:Journal of Attention Disorders, Ahead of Print. Objective:Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited.Methods:We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children's-Sleep-Habits-Questionnaire (CSHQ).Results:1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found.Conclusion:Our findings support that sleep-problems are common in ADHD, but don't suggest significant negative long-term effects of MPH on sleep.
psychiatry,psychology, developmental